EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emerging Immune Checkpoints Beyond PD-1/PD-L1 in Solid Tumor Immunotherapy

Alina Svoboda, Amandine Marchand, Milan Oliveira

Fundamental Scientific Reports in Multidisciplinary Areas · 01.05.2026 · 2 (01) · 206-215

DOI: 10.66238/fsrma77 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental Scientific Reports in Multidisciplinary Areas, online erschienen am 01.05.2026. Verfasst von Alina Svoboda und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of oncological therapeutics has been fundamentally transformed by the advent of immune checkpoint inhibitors, particularly those targeting the programmed cell death protein 1 and its primary ligand. Despite the unprecedented and durable clinical responses observed in a subset of patients across various solid malignancies, primary and acquired resistance remain formidable challenges, thereby limiting the universal applicability of these therapeutic modalities. This comprehensive academic paper investigates the biological mechanisms, preclinical validation, and clinical trajectory of emerging immune checkpoints that function beyond traditional pathways. We systematically evaluate the structural characteristics, ligand interactions, and signaling cascades of novel co-inhibitory receptors, including Lymphocyte-activation gene 3, T-cell immunoglobulin and mucin-domain containing-3, T cell immunoreceptor with Ig and ITIM domains, and V-domain Ig suppressor of T cell activation. Through a detailed analytical framework encompassing pan-cancer transcriptomic profiling and clinical trial meta-analyses, this study elucidates the complex temporal and spatial expression patterns of these molecules within the tumor microenvironment. Our findings indicate that the concurrent expression of these alternative checkpoints often serves as a compensatory resistance mechanism following conventional immunotherapy. Furthermore, we provide an extensive discussion on the synergistic potential of combinatorial blockade strategies designed to overcome immune exhaustion and restore robust anti-tumor effector functions. The integration of high-dimensional biomarker discovery and precision immunology is emphasized as a critical requisite for optimizing patient stratification and mitigating immune-related adverse events in the next generation of solid tumor immunotherapy.

Zitieren

APA

Svoboda, A., Marchand, A., & Oliveira, M. (2026). Emerging Immune Checkpoints Beyond PD-1/PD-L1 in Solid Tumor Immunotherapy. Fundamental Scientific Reports in Multidisciplinary Areas, 2(01), 206-215. https://doi.org/10.66238/fsrma77

Vancouver

Svoboda A, Marchand A, Oliveira M. Emerging Immune Checkpoints Beyond PD-1/PD-L1 in Solid Tumor Immunotherapy. Fundamental Scientific Reports in Multidisciplinary Areas. 2026;2(01):206-215. doi:10.66238/fsrma77

BibTeX
@article{Svoboda2026,
  author = {Svoboda, Alina and Marchand, Amandine and Oliveira, Milan},
  title = {Emerging Immune Checkpoints Beyond PD-1/PD-L1 in Solid Tumor Immunotherapy},
  journal = {Fundamental Scientific Reports in Multidisciplinary Areas},
  year = {2026},
  volume = {2},
  number = {01},
  pages = {206--215},
  doi = {10.66238/fsrma77}
}
Kostenlos starten →